Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide.
about
Presentation of numerous viral peptides to mouse major histocompatibility complex (MHC) class I-restricted T lymphocytes is mediated by the human MHC-encoded transporter or by a hybrid mouse-human transporter"Rule of six": how does the Sendai virus RNA polymerase keep count?The Sendai virus P gene expresses both an essential protein and an inhibitor of RNA synthesis by shuffling modules via mRNA editingPeptide Vaccine: Progress and ChallengesDiscovery of CD8+ T cell epitopes in Chlamydia trachomatis infection through use of caged class I MHC tetramersAn RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse modelEnhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positionsHigh level expression of soluble glycoproteins in the allantoic fluid of embryonated chicken eggs using a Sendai virus minigenome systemFunctionally heterogeneous CD8(+) T-cell memory is induced by Sendai virus infection of mice.The activity of Sendai virus genomic and antigenomic promoters requires a second element past the leader template regions: a motif (GNNNNN)3 is essential for replicationImmunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity.Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity.Induction of cell-mediated immunity against Mycobacterium tuberculosis using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein.Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus.A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus.Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model.Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus.Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopesGranzyme B regulates antiviral CD8+ T cell responses.Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720).Host response to Sendai virus in mice lacking class II major histocompatibility complex glycoproteins.Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.Extracellular processing of peptide antigens that bind class I major histocompatibility moleculesMemory CD8+ T cells specific for a single immunodominant or subdominant determinant induced by peptide-dendritic cell immunization protect from an acute lethal viral disease.Increase in positive selection of CD8+ T cells in TAP1-mutant mice by human beta 2-microglobulin transgeneT cell priming versus T cell tolerance induced by synthetic peptides.Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytesDifferential antigen presentation regulates the changing patterns of CD8+ T cell immunodominance in primary and secondary influenza virus infections.Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.Inhibition of Sendai virus genome replication due to promoter-increased selectivity: a possible role for the accessory C proteins.DNA immunization circumvents deficient induction of T helper type 1 and cytotoxic T lymphocyte responses in neonates and during early lifeDifferential localization and function of antibody-forming cells responsive to inactivated or live-attenuated influenza virus vaccinesProtection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytesAnalysis of the primary T-cell response to Sendai virus infection in C57BL/6 mice: CD4+ T-cell recognition is directed predominantly to the hemagglutinin-neuraminidase glycoproteinA "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge.Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion.Murine cytomegalovirus interacts with major histocompatibility complex class I molecules to establish cellular infection.The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA.
P2860
Q24336610-C84A426F-6ACB-4FEC-B4F5-12A8F77D77A9Q24529099-50DA8F5D-9277-47A8-BCD1-31F1AE0134C2Q24564716-D82D37D6-A665-44FA-931D-9CB0E4C0CAB4Q26851329-3B0283C6-4A00-40B1-B83D-6F93A3D9D5DDQ27649766-FA416FD5-A574-477C-835D-9545DED85104Q29365281-0735F823-50D2-419C-BF2C-48ECEC4867D7Q30448796-0F285A51-A751-4A89-9F83-98107415059EQ33281306-B7A3EEEA-F90A-4A10-A6FC-D6878E693FAAQ33649172-9B6D24EE-CC4E-4130-B330-0913FD3DE545Q33783140-A12AE91C-193A-41FC-8E06-D4E7BC0A0140Q33785966-A2AFD345-4DD8-48FE-AFD0-A2C75D9BBAEFQ33852549-279B01E1-ECFB-47BD-ACDE-6BB8881BF62AQ34008526-581A8A6E-C201-4196-9FA2-F68818459E0EQ34175747-F85DEC25-9AEF-407D-9A3D-A4BE438471FFQ34527878-DE998CBB-E4FE-4910-BB6C-55DDA793D39CQ34536936-102764EA-FA68-46D4-BB59-E8D291F3D0F0Q34669820-F3258AD6-25E9-4E50-868C-0B884DDBA02CQ34975904-DF9330BA-3706-49CC-92AE-E98525172105Q34998462-DAED6843-94F6-4374-9FED-421C15FA3AA5Q35093159-E32AD2F6-493B-4D8E-A732-452FBA50D8E7Q35613097-E7D4E240-F5C0-455C-9536-8003BCF175D2Q35833323-897952EF-6454-4C33-9AA2-C2B694CB2559Q35833742-B7CC7906-F40B-431F-BEBB-C99C5104E541Q36119828-DA5BAE0F-BAF9-4A11-A716-032E307F71D5Q36231285-A4533050-56A4-4E1B-916B-7CCB62DA670EQ36246319-2FB99705-E954-4D4F-BF21-A9A92E72DED9Q36364433-3FB06E1A-856F-4B44-AC4C-9DFD7134E003Q36365135-9CBF57A1-2D05-49E2-9B28-A67663CBC1D5Q36367022-DF72D445-0D71-4FB3-8D5F-99AACA3F5769Q36371363-26EF357E-46C7-4A88-9B3D-02E088642D60Q36380515-7512CBC3-D81F-4845-9E0E-2A4E4F407CD6Q36549060-8619EE97-64B5-45F9-BFE4-FA01D5AA7A3EQ36556802-432E6027-EACF-4EE0-AED3-3F232DF1B7BCQ36629013-6F2D5567-ED4B-4DCC-8CC9-AC91FF2E7C45Q36633955-DB73CD49-FA80-40EF-8741-5BE16BFEC289Q36636756-D50C81D1-FBF4-479A-826C-362326D8DE3DQ36639515-F9498EF3-FA4C-40CF-8CD7-6758D03A4A62Q36647277-D7116A3F-0C48-4441-BA8F-E6FEF51DE070Q36650212-83C1B1CA-341C-452D-92EA-55F3A4073DF3Q36651219-8DF81D05-215A-4F37-919D-AE9D525F7257
P2860
Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Protection against lethal Send ...... with a free synthetic peptide.
@en
Protection against lethal Send ...... with a free synthetic peptide.
@nl
type
label
Protection against lethal Send ...... with a free synthetic peptide.
@en
Protection against lethal Send ...... with a free synthetic peptide.
@nl
prefLabel
Protection against lethal Send ...... with a free synthetic peptide.
@en
Protection against lethal Send ...... with a free synthetic peptide.
@nl
P2093
P2860
P921
P356
P1476
Protection against lethal Send ...... with a free synthetic peptide.
@en
P2093
Kolakofsky D
Voordouw AC
P2860
P304
P356
10.1073/PNAS.88.6.2283
P407
P577
1991-03-01T00:00:00Z